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First European implantation of the new, thin-strut, 
sirolimus-eluting bioresorbable scaffold
Pierwsze europejskie wszczepienie stentu bioresorbowalnego nowej generacji  
o małej średnicy przęsła
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A 46-year-old man with coronary artery disease, hypertension, type 2 diabetes, hyperlipidaemia, and obesity was admitted 
for an elective percutaneous angioplasty of the mid segment of the first marginal branch (Fig. 1A). The haemodynamic 
significance of the lesion was confirmed with fractional flow reserve assessment (FFF = 0.74). Percutaneous coronary 
intervention was performed with the new, thin-strut, sirolimus-eluting bioresorbable scaffold (BRS) Fantom™ (Reva, US). 
The structure of the device is made of desaminotyrosine-derived polycarbonate with a strut thickness of 125 µm. The 
base structure is covered with a thin layer of desaminotyrosine-derived polycarbonate biodegradable polymer with in-
tegrated sirolimus at a total dose of 115 µg for the 3.0 × 18 mm scaffold. More than 80% of the total sirolimus load is 
eluted within the first 90 days. After predilatation with a 3.0 × 15 mm balloon (18 atm), a Fantom BRS 3.0 × 18 mm 
was implanted at a pressure of 18 atm. A high-pressure post-dilatation with a non-compliant balloon 3.0 × 12 mm was 
performed (22 atm) with good angiographic result (Fig. 1B, C). The optical coherence tomography imaging confirmed 
a very good device expansion and strut apposition along the entire scaffold length (Fig. 1D, E). The patient was discharged 
on the next day and scheduled for clinical and angiographic follow-up. This is the first report on the implantation of this 
new thin-strut BRS in humans. 
Figure 1. A. A coronary angiogram 
showing a significant lesion in the 
proximal segment of the first marginal 
branch; B. Implantation of bioresorbab-
le scaffold 3.0 × 18 mm (Fantom TM, 
REVA, US); C. A coronary angiogram 
showing good angiographic effect after 
scaffold implantation; D. A vertical 
cross sectional image from optical 
coherent tomography (OCT) confirming 
good struts apposition; E. A longitu-
dinal vessel cross section after scaffold 
implantation visualized in the OCT
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